Go Deep
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 8,815 | 39.2 | 22.99 | 2.21 | 22,503.33 |
| Oct 2026 | 9,152 | 38.3 | 22.43 | 2.21 | 21,735.02 |
| Oct 2026 | 10,446 | 37.7 | 22.12 | 2.21 | 21,315.21 |
| Oct 2026 | 10,408 | 37.9 | 22.18 | 2.21 | 21,312.86 |
| Oct 2026 | 9,837 | 39.3 | 23.13 | 2.21 | 22,223.73 |
| Oct 2026 | 9,969 | 39.1 | 22.91 | 2.21 | 21,957.77 |
| Oct 2026 | 9,881 | 39.3 | 23.05 | 2.21 | 22,119.71 |
| Oct 2026 | 10,009 | 38.9 | 22.80 | 2.21 | 21,875.09 |
| Oct 2026 | 10,322 | 38.0 | 22.24 | 2.21 | 21,290.45 |
| Oct 2026 | 10,192 | 38.3 | 22.46 | 2.21 | 21,453.15 |
Alnylam Pharmaceuticals, Inc. Quarterly Results
Quarterly data isn't available for this company right now.
Alnylam Pharmaceuticals, Inc. Revenue & Profit
Annual financial data isn't available for this company right now.
Alnylam Pharmaceuticals, Inc. Balance Sheet
Balance sheet data isn't available for this company right now.
Owes vs Owns
Alnylam Pharmaceuticals, Inc. owed $0.76 for every $1 it owned in Jun 2026, down from $1.04 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.76× | 0.84× | 0.98× | 1.06× | 1.04× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Alnylam Pharmaceuticals, Inc. Cash Flow
Cash flow data isn't available for this company right now.